Pazopanib (P) or placebo in completely resected stage I NSCLC patients: Survival results of the phase II trial IFCT-0703 - Benjamin Besse, Julien Mazieres, Laureen Ribassin-Majed, Fabrice Barlesi, Jaafar Bennouna, Radj Gervais, Lionel Moreau, Henri Berard, Didier Debieuvre, Oliver Molinier, Denis Moro-Sibilot, Pierre Jean Souquet, Jean-Pierre Pignon, Elodie Amour, Aljosa Celebic - Dissemin

Dissemin is shutting down on January 1st, 2025

Language
Login

Published in

American Society of Clinical Oncology, Journal of Clinical Oncology, 15_suppl(33), p. 7510-7510, 2015

DOI: 10.1200/jco.2015.33.15_suppl.7510

Links

Tools

Export citation

Search in Google Scholar

Pazopanib (P) or placebo in completely resected stage I NSCLC patients: Survival results of the phase II trial IFCT-0703

Journal article published in 2015 by Benjamin Besse, Julien Mazieres, Laureen Ribassin-Majed, Fabrice Barlesi, Jaafar Bennouna, Radj Gervais, Lionel Moreau, Henri Berard, Didier Debieuvre, Oliver Molinier, Denis Moro-Sibilot, Pierre Jean Souquet, Jean-Pierre Pignon, Elodie Amour, Aljosa Celebic and other authors.

This paper is made freely available by the publisher.

This paper is made freely available by the publisher.

Full text: Download

Red circle

Preprint: archiving forbidden

Orange circle

Postprint: archiving restricted

Upload

Red circle

Published version: archiving forbidden

Policy details

Data provided by

SHERPA/RoMEO